{"id":50335,"date":"2025-12-10T18:13:54","date_gmt":"2025-12-10T10:13:54","guid":{"rendered":"https:\/\/flcube.com\/?p=50335"},"modified":"2025-12-10T18:13:55","modified_gmt":"2025-12-10T10:13:55","slug":"lees-pharm-staccato-obt-acquisition-bolsters-ucb-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50335","title":{"rendered":"Lee&#8217;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership"},"content":{"rendered":"\n<p><strong>Lee&#8217;s Pharmaceutical Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0950:HKG\">HKG: 0950<\/a>) announced that its wholly\u2011owned subsidiary <strong>Nova Pneuma Inc. (NPI)<\/strong> has acquired assets from <strong>Alexza Pharmaceuticals, Inc.<\/strong>, gaining full ownership of the <strong>Staccato One Breath Technology (Staccato OBT)<\/strong> platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee&#8217;s Pharm&#8217;s inhalation capabilities and includes a manufacturing partnership with <strong>UCB<\/strong> for Staccato alprazolam, currently in Phase\u202f3.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acquisition-summary-amp-strategic-assets\">Acquisition Summary &amp; Strategic Assets<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Lee&#8217;s Pharmaceutical (via Nova Pneuma Inc.)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Alexza Pharmaceuticals assets<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Staccato OBT platform (excipient-free, rapid-onset inhalation)<\/td><\/tr><tr><td><strong>Key Products<\/strong><\/td><td>Staccato alprazolam (Phase\u202f3, epilepsy), Adasuve (commercial, acute agitation)<\/td><\/tr><tr><td><strong>Included Rights<\/strong><\/td><td>IP, know-how, trademarks, GMP facility access, worldwide licensing rights<\/td><\/tr><tr><td><strong>UCB Partnership<\/strong><\/td><td>Lee&#8217;s Pharma to receive milestones up to <strong>USD\u202f60.5\u202fmillion<\/strong> + tiered royalties + manufacturing revenue<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-staccato-obt-technology-amp-product-pipeline\">Staccato OBT Technology &amp; Product Pipeline<\/h2>\n\n\n\n<p><strong>Technology Profile:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delivery Method<\/strong>: Aerosolized inhalation in a single breath<\/li>\n\n\n\n<li><strong>Onset<\/strong>: As fast as intravenous injection, but non-invasive<\/li>\n\n\n\n<li><strong>Advantage<\/strong>: Rapid therapeutic effect without needles<\/li>\n<\/ul>\n\n\n\n<p><strong>Product Pipeline:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Staccato alprazolam<\/strong>: Phase\u202f3 for rapid relief of epileptic seizures (UCB holds global rights)<\/li>\n\n\n\n<li><strong>Adasuve<\/strong>: Approved for acute agitation in adult schizophrenia\/bipolar I disorder<\/li>\n\n\n\n<li><strong>Additional Assets<\/strong>: Clinical-stage pipeline products included in acquisition<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ucb-partnership-amp-financial-terms\">UCB Partnership &amp; Financial Terms<\/h2>\n\n\n\n<p><strong>UCB Agreement Structure:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin<\/strong>: UCB acquired Engaged Therapeutics in June\u202f2020 for Staccato alprazolam<\/li>\n\n\n\n<li><strong>Rights<\/strong>: UCB retains global development and commercialization rights<\/li>\n\n\n\n<li><strong>Lee&#8217;s Pharma Role<\/strong>: Exclusive manufacturer for worldwide supply<\/li>\n\n\n\n<li><strong>Financial Terms<\/strong>: Up to <strong>USD\u202f60.5\u202fmillion<\/strong> in milestones + tiered royalties on global net sales + manufacturing revenue<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Revenue<\/strong>: Immediate revenue stream from worldwide product supply<\/li>\n\n\n\n<li><strong>Milestone Upside<\/strong>: Potential for significant payments upon Phase\u202f3 completion and approvals<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Partnership with global pharma validates Staccato OBT technology<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-global-expansion-strategy\">Market Impact &amp; Global Expansion Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inhalation Market<\/strong>: China respiratory drug delivery market valued at <strong>\u00a512\u202fbillion<\/strong> (\u2248\u202fUS$1.7\u202fbillion), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: Staccato OBT is unique, highly differentiated technology with broad applicability<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Acquisition adds multiple clinical-stage assets to Lee&#8217;s portfolio<\/li>\n\n\n\n<li><strong>Global Ambition<\/strong>: Manufacturing for UCB positions Lee&#8217;s as key supplier in global CNS market<\/li>\n\n\n\n<li><strong>R&amp;D Synergy<\/strong>: Platform can be applied to Lee&#8217;s proprietary pipeline, accelerating development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Staccato OBT platform integration, manufacturing capabilities, and milestone payment timelines. Actual results may differ due to regulatory, manufacturing, and partnership execution risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lee&#8217;s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1875,941,165,4494],"class_list":["post-50335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alexza-pharmaceuticals","tag-hkg-0950","tag-lees-pharmaceutical","tag-nova-pneuma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lee&#039;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lee&#039;s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee&#039;s Pharm&#039;s inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee&#039;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership\" \/>\n<meta property=\"og:description\" content=\"Lee&#039;s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee&#039;s Pharm&#039;s inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T10:13:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T10:13:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee&#8217;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership\",\"datePublished\":\"2025-12-10T10:13:54+00:00\",\"dateModified\":\"2025-12-10T10:13:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1001.webp\",\"keywords\":[\"Alexza Pharmaceuticals\",\"HKG: 0950\",\"Lee's Pharmaceutical\",\"Nova Pneuma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50335#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50335\",\"name\":\"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1001.webp\",\"datePublished\":\"2025-12-10T10:13:54+00:00\",\"dateModified\":\"2025-12-10T10:13:55+00:00\",\"description\":\"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee's Pharm's inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50335\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee&#8217;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee's Pharm's inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50335","og_locale":"en_US","og_type":"article","og_title":"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership","og_description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee's Pharm's inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.","og_url":"https:\/\/flcube.com\/?p=50335","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-10T10:13:54+00:00","article_modified_time":"2025-12-10T10:13:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee&#8217;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership","datePublished":"2025-12-10T10:13:54+00:00","dateModified":"2025-12-10T10:13:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50335"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","keywords":["Alexza Pharmaceuticals","HKG: 0950","Lee's Pharmaceutical","Nova Pneuma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50335#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50335","url":"https:\/\/flcube.com\/?p=50335","name":"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50335#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","datePublished":"2025-12-10T10:13:54+00:00","dateModified":"2025-12-10T10:13:55+00:00","description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly\u2011owned subsidiary Nova Pneuma Inc. (NPI) has acquired assets from Alexza Pharmaceuticals, Inc., gaining full ownership of the Staccato One Breath Technology (Staccato OBT) platform, including pipeline products, intellectual property, and manufacturing rights. The deal strengthens Lee's Pharm's inhalation capabilities and includes a manufacturing partnership with UCB for Staccato alprazolam, currently in Phase\u202f3.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50335"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50335#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","width":1080,"height":608,"caption":"Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee&#8217;s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50335\/revisions"}],"predecessor-version":[{"id":50337,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50335\/revisions\/50337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50336"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}